Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$7.56 USD
-0.30 (-3.82%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.54 -0.02 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCYC 7.56 -0.30(-3.82%)
Will BCYC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
Other News for BCYC
Bicycle Therapeutics (BCYC) Target Price Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics (BCYC) Price Target Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics price target lowered by $7 at RBC Capital, here's why
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCYC ...